Vensana Capital Closes $325M Second Fund
Gunderson Dettmer represented client Vensana Capital in the formation of its $325 million second fund, Vensana Capital II. The new fund will enable the firm to scale up its investments in medtech companies in both the development and commercial stage.
In the announcement of the fund, Managing Partner Justin Klein said, “Medical technology innovations have the ability to dramatically improve healthcare quality and outcomes while simultaneously reducing costs. We believe Vensana has both a tremendous opportunity and a responsibility to support our entrepreneurs in their pursuit of technologies and businesses that will transform healthcare for the future.”
The Gunderson deal team was led by Nicholas Guttilla and included Tyler Kirtley and David Myerson.